Title: Status of Serum Leptin and Lipid Profile in Newly Diagnosed Psoriasis Patients: A Case Control Study
Authors: Ghalaut VS, Sarkar M, Dayal S, Gupta G, Samanta S, Rajju T
DOI: http://dx.doi.org/10.18535/jmscr/v4i3.41
Abstract
Objective: Psoriasis is an autoimmune chronic inflammatory disease involving the skin and mucous membranes. Besides the autoimmune and genetic factors many stressful physiologic, psychological events and environmental factors play an important role in disease etiopathogenesis. Leptin, an adipocyte-derived hormone, plays a role in immune responses and may be involved in the pathogenesis of psoriasis. Psoriasis is associated with variety of lipid profile disorders. So, we performed this study to determine serum leptin levels and lipid profile in psoriasis patients.
Material and methods: We conducted a prospective case control study from February 2014 to April 2015 on 30 patients of psoriasis and 30 age and sex match healthy control subjects. We measured serum leptin level by ELISA technique and lipid profile by enzymatic method.
Results: Serum leptin and lipid profile of total 60 subjects, 30 patients of psorisis and 30 age and sex match healthy volunteers were analysed in this study. Leptin level was found to be significantly higher in psorisis group as compared to healthy volunteers (p <0.05).We also found significantly higher leptin level in psoriasis patients with higher PASI (Psoriasis Area and Severity Index) score (> 15) compared to low PASI score (< 15).Among lipid profile parameters TC, TG, LDL-C and VLDL-C were significantly higher in psoriasis group compared to healthy control (p<0.05). HDL-C level was significantly lower in psoriasis patients compared to healthy controls (p <0.05).
Conclusion: Psoriasis is associated with hyperleptinemia. Higher leptin level was found in patients with higher PASI score. Thus, it may have role in the pathogenesis or severity of psoriasis. Dyslipidemia is also common in psoriasis. We recommend early monitoring of both leptin and lipid profile in these patients to prevent development of metabolic syndrome and long term cardiovascular events. We suggest more large scale studies in psoriasis patients to establish it.
References
1. Oka A, Mabuchi T, Ozawa A et al. Current understanding of human genetics and genetic analysis of psoriasis. J Dermat 2012;39:231-41.
2. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-71.
3. Gudjonsson JE, Elder JT. Psoriasis: epidemiology. ClinDermatol 2007; 25(6):535-546.
4. Menter A, Gottlieb A, Feldman SRet al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am AcadDermatol 2008;58(5):826-850.
5. Hercogová J, Ricceri F, Tripo L et al. Psoriasis and body mass index. DermatolTher 2010;23:152-4.
6. Maffei M, Halaas J, Ravussin Eet al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995;1:1155–61.
7. Wang Y, Chen J, Zhao Y et al. Psoriasis is associated with increased levels of serum leptin. Br J Dermatol 2008;158:1134–5.
8. Frühbeck G. Intracellular signalling pathways activated by leptin.Biochem J 2006; 393:7-20.
9. Garofalo C, Surmacz E. Leptin and cancer. J Cell Physiol 2006;207:12-22.
10. Coimbra S, Oliveira H, Reis F et al. Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. J EurAcadDermatolVenereol 2010;24:1386–94.
11. Cerman AA, Bozkurt S, SavAet al. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br J Dermatol 2008; 159:820–6.
12. Zayed AA, Maksoud NA, Ragab HM. Psoriasis vulgaris severity and body mass index: evaluating therole of leptin, tumor necrosis factor-α and interleukin-6. Journal of the Egyptian Women’s Dermatologic Society 2012;9:86–91.
13. Love TJ, Qureshi AA, Karlson EW et al. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003–2006. Arch Dermatol 2011; 147:419–24.
14. Gelfand JM, Neimann AL, Shin DB et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296:1735–41.
15. Krueger JG. Hiding under the skin: A welcome surprise in psoriasis. Nat Med 2012; 18:1750–1.
16. Pietrzak A, Michalak-Stoma A, Chodorowska G et al. Lipid disturbances in psoriasis: an update. Mediators Inflamm 2010;53:6-12.
17. Imagawa K, Matsumoto Y, Numata Yet al. Development of a sensitive ELISA for human leptin, using monoclonal antibodies. ClinChem 2001;47:1579-96.
18. Warnick GR, Nauch M, Rifai N. Evolution of method for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. ClinChem 2001; 47:1579-96.
19. Rifai N, Iannotti E, DeAngelis K et al. Analytical and clinical performance of a homogeneous enzymatic LDL-cholesterol assay compared with the ultracentrifugation-dextran sulphate-Mg++ method. ClinChem 1998; 44:1242-50.
20. Takahashi H, Tsuji H, Takahashi I et al. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol 2008;159:1207–8.
21. Enany B, ElZohiery AK, Elhilaly R et al. Carotid intima-media thickness and serum leptin in psoriasis. Herz 2012;37:527-33.
22. Zhu KJ, Zhang C, Li M et al.Leptin levels in patients with psoriasis: a meta-analysis. ClinExpDermatol 2013;38:478-83.
23. Y J Oh, HK Lim, JH Choi et al. Serum Leptin and Adiponectin Levels in Korean Patients with Psoriasis. J Korean Med Sci 2014; 29: 729-34.
24. Aktan S, Rota S, Erdogan BS et al. A Role OfLeptin in Psoriasis. Turk J Med Sci 2007;37:135-8.
25. Weigle N, McBane S. Psoriasis. Am Fam Physician 2013;87:626-33.
26. Considine RV, Sinha MK, Heiman MLet al. Serum immunoreactive- leptin concentrations in normal-weight and obese humans. New Engl J Med 1996;334:292-5.
27. Müller G, Ertl J, GerlM et al. Leptin impairs metabolic actions of insulin in isolated rat adipocytes. J BiolChem 1997;272:10585–93.
28. Zhao AZ, Shinohara MM, Huang Det al. Leptin induces insulin-like signaling that antagonizes cAMP elevation by glucagon in hepatocytes. J BiolChem 2000;275: 11348–54.
29. Frühbeck G. Intracellular signalling pathways activated by leptin.Biochem J 2006; 393:7-20.
30. Motta S, Monti M, Sesana S et al. Abnormality of water barrier function in psoriasis. Role of ceramide fractions.Arch Dermatol 1994;130:452-6.
31. Pietrzak A, Chodorowska G, Szepietowski J et al. Psoriasis and serum lipid abnormalities. DermatolTher 2010;23:160–73.
32. Mallbris L, Granath F, Hamsten A et al. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am AcadDermatol 2006;54:614–21.
33. Piskin S, Gurkok F, Ekuklu G et al. Serum lipid levels in psoriasis. Yonsei Med J 2003;44:24–6.
34. VanizorKural B, Orem A, Cimsit GU et al. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis. Clinica ChemicaActa2003;328:71–82.
35. Tekin NS, Tekin IO, Barut F et al. Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflamm 2007;2007:78454.
36. Rocha-Pereira P, Santos-Silva A, Rebelo I et al. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clinica Chimica Acta 2001;303:33–39.
37. Reynoso-von Drateln C, Martínez-Abundis E, Balcázar-Muñoz BR et al. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol 2003;48:882-5.
38. Ferretti G, Simonetti O, Offidani AM et al. Changes of plasma lipids and erythrocyte membrane fluidity in psoriatic children. Pediatr Res 1993;33:506-9.
39. Mehta NN, Li R, Krishnamoorthy P et al. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis 2012;224:218-21.
40. Holzer M, Wolf P, Curcic S et al. Psoriasis alters HDL composition and cholesterol efflux capacity. J Lipid Res 2012;53:1618-24.
41. Kumari A, Suman B. Sharma, SingalA et al. Association of carotid intima-media thickness with leptin and apolipoprotein b/apolipoprotein a-i ratio reveals imminent predictors of subclinicalatherosclerosis in psoriasis patients. Actamedica 2014; 57:21–7.
42. Kalkan G, Karadag S. Cardiovascular risk in psoriasis. Eur J Gen Med 2013;10:10-6.